PMID- 24047479
OWN - NLM
STAT- MEDLINE
DCOM- 20150129
LR  - 20211021
IS  - 1029-2403 (Electronic)
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 55
IP  - 4
DP  - 2014 Apr
TI  - Genomic imbalance defines three prognostic groups for risk stratification of 
      patients with chronic lymphocytic leukemia.
PG  - 920-8
LID - 10.3109/10428194.2013.845882 [doi]
AB  - Array comparative genomic hybridization (aCGH) has yet to be fully leveraged in a 
      prognostic setting in chronic lymphocytic leukemia (CLL). Genomic imbalance was 
      assessed in 288 CLL specimens using a targeted array. Based on 20 aberrations in 
      a hierarchical manner, all 228 treatment-naive specimens were classified into a 
      group with poor outcome (20.6%) exhibiting at least one aberration that was 
      univariately associated with adverse outcome (gain: 2p, 3q, 8q, 17q, loss: 7q, 
      8p, 11q, 17p, 18p), good outcome (32.5%) showing 13q14 loss without any of the 
      other 10 aberrations (gain: 1p, 7p, 12, 18p, 18q, 19, loss: 4p, 5p, 6q, 7p) or 
      intermediate outcome (remainder). The three groups were significantly separated 
      with respect to time to first treatment and overall survival (p < 0.001), and 
      validation of the stratification scheme was performed in two independent 
      datasets. Gain of 3q and 8q, and 17p loss were determined to be independent 
      unfavorable prognostic biomarkers. TP53, NOTCH1 and SF3B1 mutations correlated 
      with the presence of one poor outcome aCGH marker, at a considerably higher 
      frequency than when only considering poor risk aberrations routinely detected by 
      fluorescence in situ hybridization (FISH). These data support genomic imbalance 
      evaluation in CLL by aCGH to assist in risk stratification.
FAU - Houldsworth, Jane
AU  - Houldsworth J
AD  - Cancer Genetics, Inc. , Rutherford, NJ , USA.
FAU - Guttapalli, Asha
AU  - Guttapalli A
FAU - Thodima, Venkata
AU  - Thodima V
FAU - Yan, Xiao Jie
AU  - Yan XJ
FAU - Mendiratta, Geetu
AU  - Mendiratta G
FAU - Zielonka, Tania
AU  - Zielonka T
FAU - Nanjangud, Gouri
AU  - Nanjangud G
FAU - Chen, Weiyi
AU  - Chen W
FAU - Patil, Sujata
AU  - Patil S
FAU - Mato, Anthony
AU  - Mato A
FAU - Brown, Jennifer R
AU  - Brown JR
FAU - Rai, Kanti
AU  - Rai K
FAU - Chiorazzi, Nicholas
AU  - Chiorazzi N
FAU - Chaganti, R S K
AU  - Chaganti RS
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20131112
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Immunoglobulin Heavy Chains)
SB  - IM
MH  - Biomarkers, Tumor/genetics
MH  - *Chromosome Aberrations
MH  - Chromosome Deletion
MH  - Chromosomes, Human, Pair 13
MH  - Comparative Genomic Hybridization
MH  - Datasets as Topic
MH  - Female
MH  - *Genomics
MH  - Humans
MH  - Immunoglobulin Heavy Chains/genetics
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis/*genetics/mortality
MH  - Male
MH  - Mutation
MH  - Neoplasm Staging
MH  - Patient Outcome Assessment
MH  - Prognosis
PMC - PMC6905429
MID - NIHMS925123
COIS- Potential conflict of interest: Disclosure forms provided by the authors are 
      available with the full text of this article at www.informahealthcare.com/lal.
EDAT- 2013/09/21 06:00
MHDA- 2015/01/30 06:00
PMCR- 2019/12/11
CRDT- 2013/09/20 06:00
PHST- 2013/09/20 06:00 [entrez]
PHST- 2013/09/21 06:00 [pubmed]
PHST- 2015/01/30 06:00 [medline]
PHST- 2019/12/11 00:00 [pmc-release]
AID - 10.3109/10428194.2013.845882 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2014 Apr;55(4):920-8. doi: 10.3109/10428194.2013.845882. Epub 2013 
      Nov 12.